FDA Offers New ‘cGMP Declarations’ That Could Fill US Gap In EU GMP Certificates
Executive Summary
US FDA will send ‘cGMP declarations’ to regulatory authorities in other countries where firms want to market drug products made in the US. There is some hope that the declarations will fill in for EU GMP certificates no longer issued for US manufacturing facilities now that there is a US/EU mutual recognition agreement on inspections.
You may also be interested in...
FDA CDER Compliance Office Answered Pandemic With Fewer Inspections, Greater Discretion
Fewer inspections but more warning letters, import alerts and drug-shortage discretions were seen as office sought to ameliorate COVID-19 impacts.
EMA Drops 130 US Manufacturing Site Inspections Under Landmark MRA
The European Medicines Agency says it is too early to speculate on when the EU will recognize the first US Food and Drug Administration inspection under the mutual recognition agreement signed last year.
US FDA Training Up Inspectorate To Oversee Quality Of Novel Manufacturing Technologies
Agency is hiring contractor to identify gaps in the ability of inspectors, investigators and compliance officers to oversee manufacturing quality in the context of new and emerging technologies – and to identify organizations that could fill the gaps through training.